Urgent.News

the world's headlines, one feed

Editions

Health & Medicine

Polio can return in 10 years if vaccination stops — Rotary President, Babalola

Rotary President Yinka Babalola warns polio could return in a decade if vaccination efforts cease. Learn about Rotary’s fight against polio and global heal Read More: https://punchng.com/polio-can-return-in-10-years-if-vaccination-stops-rotary-president-babalola/

Polio can return in 10 years if vaccination stops — Rotary President, Babalola

Yinka Babalola, President of Rotary International, shared his vision for the organization's next year of leadership and the critical importance of sustaining humanitarian interventions. He emphasized the organization's commitment to creating lasting impact, not just in service to others, but also as a transformative experience for personal growth.

Rotary's focus areas include community development, economic empowerment, basic education, water and sanitation, among others. The organization's involvement in polio eradication, a flagship project since 1988, has contributed to a remarkable 99.9% decrease in cases worldwide, with only Pakistan and Afghanistan still considered endemic.

Babalola stressed the importance of continued efforts to eradicate polio, as the disease maims or kills children daily, underscoring Rotary's role in fundraising, advocacy, and mobilizing volunteers for this vital cause.

Written by urgent.news from Punch's reporting — not their text. Machine-written — it may contain errors, so check the original before relying on it.

Read the original at punchng.com →

More in Health & Medicine

JW Pharmaceutical’s Gout Drug Candidate Outperforms Febuxostat in Phase 3 Trial

JW Pharmaceutical has reported positive results from a multinational Phase 3 trial of its gout drug candidate epaminurad (code name URC102), with the 6mg dose demonstrating statistically superior…

  • JW Pharmaceutical's epaminurad (URC102) outperformed febuxostat in Phase 3 gout trial.
  • Epaminurad achieved 50.0% serum uric acid reduction vs. 38.3% for febuxostat 40mg.
  • Safety profiles were comparable with no drug-related deaths reported.